Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

NARecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 25, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Neuromyelitis Optica Spectrum Disorders
Interventions
DEVICE

Protein A immunoadsorption

The experimental group was treated with a combination of protein A immunoadsorption and intravenous methylprednisolone. The methylprednisolone was administered following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day. Protein A immunoadsorption was conducted every other day, unless a physician determined that the patient's condition was unsuitable for treatment, in which case treatment was administered according to medical advice. A total of 5 treatments were given, with each session involving the regeneration of plasma at 1 to 3 times the plasma volume.

DRUG

intravenous methylprednisolone

The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.

Trial Locations (1)

518000

RECRUITING

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangdong 999 Brain Hospital

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

collaborator

Beijing Friendship Hospital

OTHER

lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER